Dr. Rany Aburashed is the founder and CEO of Neurogen Biomarking, as well as the Corporate Chair of Neurology, Corporate Chief Medical Officer, and Chief of Sub-Specialty Services at the Insight Hospital and Medical Center. He completed his undergraduate studies in Psychology and World Religion at Albion College, and attended Michigan State University’s College of Osteopathic Medicine, where he earned his medical doctorate in 2006.
He has extensive research experience in the neuroimmunology space, having served as the primary investigator on over 30 phase 1-4 clinical trials. He is widely recognized for his pioneering work using single-molecule array assay technology to assess protein biomarkers in multiple sclerosis (MS) patients. Dr. Aburashed’s primary research interest lies in precision disease management, focusing on neurofilament light and biomarker profiles to better understand treatment effects in MS. Additionally, his work extends to the development of biomarkers for the early detection of neurodegenerative diseases, a field in which he is highly active. Through his contributions, Dr. Aburashed continues to push the boundaries of biomarker research, aiming to improve diagnosis, treatment, and outcomes for patients with neurological conditions.
Dr. Rany Aburashed is the founder and CEO of Neurogen Biomarking, as well as the Corporate Chair of Neurology, Corporate Chief Medical Officer, and Chief of Sub-Specialty Services at the Insight Hospital and Medical Center. He completed his undergraduate studies in Psychology and World Religion at Albion College, and attended Michigan State University’s College of Osteopathic Medicine, where he earned his medical doctorate in 2006.
He has extensive research experience in the neuroimmunology space, having served as the primary investigator on over 30 phase 1-4 clinical trials. He is widely recognized for his pioneering work using single-molecule array assay technology to assess protein biomarkers in multiple sclerosis (MS) patients. Dr. Aburashed’s primary research interest lies in precision disease management, focusing on neurofilament light and biomarker profiles to better understand treatment effects in MS. Additionally, his work extends to the development of biomarkers for the early detection of neurodegenerative diseases, a field in which he is highly active. Through his contributions, Dr. Aburashed continues to push the boundaries of biomarker research, aiming to improve diagnosis, treatment, and outcomes for patients with neurological conditions.